2021 EASL意见书：肝细胞癌的系统治疗

2021-10-07 欧洲肝脏研究学会 J Hepatol

2021年10月，欧洲肝脏研究学会(EASL)发布了肝细胞癌的系统治疗意见书。

中文标题：

英文标题：

Systemic treatment of hepatocellular carcinoma: An EASL position paper

发布机构：

欧洲肝脏研究学会

发布日期：

2021-10-07

简要介绍：

2021年10月，欧洲肝脏研究学会(EASL)发布了肝细胞癌的系统治疗意见书。在过去的5年中，肝细胞癌的系统治疗取得了相关的进展。本文修订了之前EASL的肝细胞癌指南，主要针对肝细胞癌的系统治疗提供指导意见。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=9734d1c002215aa6, title=2021 EASL意见书：肝细胞癌的系统治疗, enTitle=Systemic treatment of hepatocellular carcinoma: An EASL position paper, guiderFrom=J Hepatol, authorId=0, author=, summary=2021年10月，欧洲肝脏研究学会(EASL)发布了肝细胞癌的系统治疗意见书。, cover=https://img.medsci.cn/20211020/1634702337094_1608702.png, journalId=0, articlesId=null, associationId=84, associationName=欧洲肝脏研究学会, associationIntro=欧洲肝脏研究学会（European Association for the Study of the Liver,EASL），是目前在欧洲居于首要地位的肝病学会，其发布的指南包括各种肝病的处理，同时对诊断、治疗和预防方法进行规范化定义。该协会下属的指南组按疾病划分为肝细胞癌、乙肝、丙肝、酒精性肝病、急性肝衰竭和威尔逊氏病等。其协会官方期刊《Journal of Hepatology》为月刊。, copyright=0, guiderPublishedTime=Thu Oct 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月，欧洲肝脏研究学会(EASL)发布了肝细胞癌的系统治疗意见书。在过去的5年中，肝细胞癌的系统治疗取得了相关的进展。本文修订了之前EASL的肝细胞癌指南，主要针对肝细胞癌的系统治疗提供指导意见。</span></p>, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=357, guiderKeyword=肝细胞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2808, appHits=42, showAppHits=0, pcHits=557, showPcHits=2766, likes=1, shares=2, comments=6, approvalStatus=1, publishedTime=Wed Oct 20 12:48:52 CST 2021, publishedTimeString=2021-10-07, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Oct 20 12:05:20 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 18:33:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EASL意见书：肝细胞癌的系统治疗.pdf)])

2021 EASL意见书：肝细胞癌的系统治疗.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1180056, encodeId=19631180056d6, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Mon Jan 03 16:28:19 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064587, encodeId=aae3106458ee5, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Thu Oct 28 09:10:58 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064081, encodeId=67791064081cc, content=好东西收藏了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50795254999, createdName=147ed37fm13暂无昵称, createdTime=Tue Oct 26 14:26:51 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
2022-01-03 一己怀

什么时候有中文

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1180056, encodeId=19631180056d6, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Mon Jan 03 16:28:19 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064587, encodeId=aae3106458ee5, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Thu Oct 28 09:10:58 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064081, encodeId=67791064081cc, content=好东西收藏了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50795254999, createdName=147ed37fm13暂无昵称, createdTime=Tue Oct 26 14:26:51 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
2021-10-28 1debd7bdm05(暂无匿称)

什么时候有中文

87 0
[GetPortalCommentsPageByObjectIdResponse(id=1180056, encodeId=19631180056d6, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Mon Jan 03 16:28:19 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064587, encodeId=aae3106458ee5, content=什么时候有中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Thu Oct 28 09:10:58 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064081, encodeId=67791064081cc, content=好东西收藏了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50795254999, createdName=147ed37fm13暂无昵称, createdTime=Tue Oct 26 14:26:51 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
2021-10-26 147ed37fm13暂无昵称

好东西收藏了

67 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021 EASL意见书：肝细胞癌的系统治疗

相关指南

拓展阅读

科室

工具

服务